scholarly journals Delavirdine Mesylate

2020 ◽  
Author(s):  
Keyword(s):  
Delavirdine Mesylate

Solid Phases of Delavirdine Mesylate

1996 ◽  
Vol 85 (8) ◽  
pp. 834-841 ◽  
Author(s):  
M.S. Bergren ◽  
R.S. Chao ◽  
P.A. Meulman ◽  
R.W. Sarver ◽  
M.A. Lyster ◽  
...  
Keyword(s):  
Solid Phases ◽  
Delavirdine Mesylate

Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients

2003 ◽  
Vol 23 (5) ◽  
pp. 323-328
Author(s):  
Gene D Morse ◽  
Susan E Cohn ◽  
Mark J Shelton ◽  
Carol Greisberger ◽  
Steven R Cox ◽  
...  
Keyword(s):  
Multiple Dose ◽  
Multiple Dose Pharmacokinetics ◽  
Delavirdine Mesylate

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

1997 ◽  
Vol 35 (1) ◽  
pp. 53-63 ◽  
Author(s):  
Marie T Borin ◽  
James H Chambers ◽  
Barbara J Carel ◽  
William W Freimuth ◽  
Sophia Aksentijevich ◽  
...  
Keyword(s):  
Pharmacokinetic Study ◽  
Hiv 1 ◽  
Delavirdine Mesylate

scholarly journals Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-Infected Patients

2003 ◽  
Vol 47 (5) ◽  
pp. 1694-1699 ◽  
Author(s):  
Mark J. Shelton ◽  
Ross G. Hewitt ◽  
John Adams ◽  
Andrew Della-Coletta ◽  
Steven Cox ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Systemic Exposure ◽  
Pharmacokinetic Parameters ◽  
Time Curve ◽  
Minimum Concentration ◽  
Mean Values ◽  
Immunodeficiency Virus ◽  
The Mean ◽  
Full Dosage ◽  
Delavirdine Mesylate

ABSTRACT To evaluate the pharmacokinetic effect of adding delavirdine mesylate to the antiretroviral regimens of human immunodeficiency virus (HIV)-infected patients stabilized on a full dosage of ritonavir (600 mg every 12 h), 12 HIV-1-infected subjects had delavirdine mesylate (400 mg every 8 h) added to their current antiretroviral regimens for 21 days. Ritonavir pharmacokinetics were evaluated before (day 7) and after (day 28) the addition of delavirdine, and delavirdine pharmacokinetics were evaluated on day 28. The mean values (± standard deviations) for the maximum concentration in serum (C max) of ritonavir, the area under the concentration-time curve from 0 to 12 h (AUC0-12), and the minimum concentration in serum (C min) of ritonavir before the addition of delavirdine were 14.8 ± 6.7 μM, 94 ± 36 μM · h, and 3.6 ± 2.1 μM, respectively. These same parameters were increased to 24.6 ± 13.9 μM, 154 ± 83 μM · h, and 6.52 ± 4.85 μM, respectively, after the addition of delavirdine (P is <0.05 for all comparisons). Delavirdine pharmacokinetic parameters in the presence of ritonavir included a C max of 23 ± 16 μM, an AUC0-8 of 114 ± 75 μM · h, and a C min of 9.1 ± 7.5 μM. Therefore, delavirdine increases systemic exposure to ritonavir by 50 to 80% when the drugs are coadministered.

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate*

1997 ◽  
Vol 61 (5) ◽  
pp. 544-553 ◽  
Author(s):  
Marie T. Borin ◽  
James H. Chambers ◽  
Barbara J. Carel ◽  
Suzanne Gagnon ◽  
William W. Freimuth
Keyword(s):  
Pharmacokinetic Study ◽  
Delavirdine Mesylate

Spectroscopic studies of delavirdine mesylate (U-90,152T) a bis(heteroaryl)piperazine (BHAP) HIV reverse transcriptase inhibitor

1996 ◽  
Vol 33 (2) ◽  
pp. 493-496 ◽  
Author(s):  
Kathleen A. Farley ◽  
Gregory S. Walker ◽  
Russell H. Robins ◽  
Jane E. Kupstas-Guido ◽  
Wayne K. Duholke ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Spectroscopic Studies ◽  
Hiv Reverse Transcriptase ◽  
Reverse Transcriptase Inhibitor ◽  
Delavirdine Mesylate
Sign in / Sign up

Export Citation Format

Share Document